LabMedica highlights new CLiMB data showing Helio’s AI-powered HelioLiver Dx blood test detects liver cancer earlier and more sensitively than ultrasound in high-risk cirrhosis patients.
This is a summary of third-party media coverage. Read the full article on LabMedica.com.
LabMedica reported on results from Helio Genomics’ pivotal CLiMB study, highlighting that the AI-powered HelioLiver Dx blood test outperformed ultrasound for the early detection of hepatocellular carcinoma (HCC) — the most prevalent form of liver cancer — in patients with liver cirrhosis.
Patients with liver cirrhosis and chronic hepatitis B are at higher risk of developing HCC, and the American Association for the Study of Liver Diseases (AASLD) recommends these high-risk patients undergo surveillance every six months. Regular testing is crucial for early cancer detection, which significantly increases the likelihood of successful treatment. Common causes of cirrhosis include hepatitis B, hepatitis C, excessive alcohol consumption, obesity, diabetes, and nonalcoholic fatty liver disease (NAFLD). While ultrasound is the standard surveillance method, many physicians consider it insufficient because of performance limitations and patient-access barriers.
The HelioLiver Dx test analyzes cell-free DNA (cfDNA) methylation patterns, serum protein biomarkers, and patient demographic data to detect HCC in cirrhotic patients. According to the coverage, the CLiMB study — which enrolled 1,968 high-risk subjects — is the largest completed prospective, multi-center clinical trial for a liver cancer detection liquid biopsy in the United States. The test met its prespecified coprimary endpoints, demonstrating superior sensitivity and non-inferior specificity compared with ultrasound, and also met a secondary endpoint by showing superior sensitivity for detecting HCC lesions up to 4 cm in diameter.
“The results from our CLiMB study clearly demonstrate the superior performance of our HelioLiver Dx test compared to ultrasound. We are thrilled with the potential of our blood-based test to detect liver cancer early leading to better patient outcomes and ultimately saving more lives.”
Read the full coverage
This article summarizes external reporting by LabMedica. For the complete write-up, visit LabMedica.com.
Source: LabMedica — “Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection.”